Novartis results for CANOPY|1 study support further evaluation of ...

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 ...

The study also demonstrated statistically significant improvements across all secondary endpoints in both the overall and monotherapy ...

Novartis Discontinues Development of NIS793 in Pancreatic Cancer

Additionally, 23% of patients (n = 28) experienced stable disease (SD), including 12 patients who had SD for more than 4 months. Fifty-nine ...

Five-year follow-up of ZUMA-1 supports the curative potential of ...

Investigator-assessed response, survival, safety, and pharmacokinetics were assessed in patients who had received treatment. The objective ...

Solidarity clinical trial for COVID-19 treatments

Available results from Solidarity Trial ... Preliminary results suggest that this drug had little or no effect on hospitalized patients with COVID ...

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus ...

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or ...

Novartis bid to repurpose rare disease drug for cancer falls short in ...

“While we are disappointed CANOPY-A did not show the benefit we hoped for, every trial generates scientific evidence that supports future ...

Novartis delivers solid Q3 results, with strong growth in Innovative ...

Ph3 CANOPY-1 study did not meet its primary endpoints in non-small ... Results support further evaluation in lung cancer. Remibrutinib ...

Page 1 of 11 Clinical Trial Results (CTR) CRTH258AUS20

Study Design/Methodology. In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was.

Novartis Suspends Phase 2 Study of Huntington Disease Agent ...

Quality of life improvements were observed, with PDQ-39 scores improving by 8 points in the high-dose group. The study's results support further ...

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in ...

Thirty-one (46.3%) patients were ≥65 years of age. Primary cancer diagnoses are listed in Table 1; the majority of patients (70.1%) had FL. More than half of ...

Preliminary results from phase Ib study of spartalizumab plus ...

ORR and complete response rate were 50% and 5.3% in B, and 51.5% and 3% in C. Median DOR (months; 95% CI) by investigator assessment was 13.8 (4.9, NE) in B and ...

ClinicalTrials.gov: Home

... study results before quality control (QC) review took place. If the ... As of January 1, 2020, initial results submissions for applicable clinical trials ...

AACR: Novartis aims to keep canakinumab's early lung cancer ...

CANOPY-1 marked the second flop for canakinumab, an FDA-approved inflammatory disease drug, in NSCLC. The interleukin-1 beta inhibitor had ...

MONARCH 3 final PFS: a randomized study of abemaciclib as initial ...

At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival ...

Novartis to sponsor large clinical trial of hydroxychloroquine in ...

The large trial sponsored by Novartis will be conducted at more than a dozen sites in the United States. Novartis plans to begin enrollment for ...

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell ...

The trial is continuing in order to evaluate outcomes with additional ... results of previous studies of PD-1 pathway inhibition in advanced NSCLC ...

BeiGene Strengthens Global Portfolio and Regains Full Rights from ...

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab). Sep 19, 2023 6:00 AM.

Five-Year Extension Results of the Phase 1 START Trial

In the original START study, 2 children who received early dosing (ie, within 3 months of birth) with onasemnogene abeparvovec achieved the ...

Novartis provides update on Phase III study evaluating ...

• The CANOPY clinical trial program is designed to help answer critical questions ... contained in this press release as a result of new ...

Novartis' canakinumab misses in another Phase III lung cancer trial

More on this story... Novartis jumps on surprise success of CANTOS ... GSK's depemokimab scores well in CRSwNP trials. 14 October 2024.